HUMAN IMMUNODEFICIENCY VIRUS SPECIFIC T-CELL IMMUNITY IN SEROPOSITIVE, ASYMPTOMATIC INDIVIDUALS

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

HUMAN IMMUNODEFICIENCY VIRUS SPECIFIC T-CELL IMMUNITY IN SEROPOSITIVE, ASYMPTOMATIC INDIVIDUALS

Vaccines 88. New Chemical and Genetic Approaches to Vaccination: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Ginsberg H et al, eds. New York, Cold Spring Harbor Laboratory, p. 291-5, 1988.. Unique Identifier : AIDSLINE ICDB/89649771
Linette G; Pierce P; Wong D; Wagner K; Smith E; Folks T; Hartzman R; Georgetown Univ. Sch. of Medicine, Washington, DC 20007

Abstract: Cellular immunity to HIV was studied in seropositive individuals in a series of experiments: (1) screening of peripheral blood lymphocytes from HIV-seropositive and control seronegative individuals for in vitro proliferative responses to recall antigens (tetanus toxoid and influenza-A); (2) in vitro responses induced by psoralen-inactivated HIV; (3) phenotype determination of the cells responding to HIV in seropositive donors; and (4) examination of the relationship between the CD4 count of individual patients (pts) and the T-cell response to HIV. Most (67%) seropositive, asymptomatic pts possess demonstrable T-cell immunity to HIV. Seropositive subjects who do not respond to tetanus toxoid (or influenza virus) also fail to respond to HIV, indicating a generalized impairment of the helper T-cell compartment that appears early during the course of the disease. No correlation between CD4 count and the in vitro proliferative response to HIV was apparent among a randomly chosen group of 12 seropositive donors. Collectively, these observations suggest that in vitro T-cell-proliferation assays to recall antigen may be the most sensitive indicator of immunologic dysfunction in seropositive subjects. Moreover, the loss of HIV-specific T-cell immunity coincides with low responsiveness to other recall antigens. Additional studies are needed to correlate HIV-specific immunity and progression of disease among Stage 1 and Stage 2 pts. (7 Refs)

Keywords: Antibody-Dependent Cell Cytotoxicity CD4-Positive T-Lymphocytes/IMMUNOLOGY Human HIV/*IMMUNOLOGY HIV Antibodies/BIOSYNTHESIS HIV Seropositivity/*IMMUNOLOGY Leukocyte Count *Lymphocyte Transformation T-Lymphocytes/*IMMUNOLOGY T-Lymphocytes, Cytotoxic/IMMUNOLOGY MEETING PAPER

890330
M8930539

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .